The Merck paper was examined more closely by Bernstein Research-Analyst Florent Cespedes.
The US analysis house Bernstein Research left the classification for Merck KGAA on “Market-Perform” with a price target of 147 euros. Apparently the USA would raise tariffs of 15 percent on brand medication, whereas generics are apparently not affected, Florent Cespedes wrote in an industry study available on Monday. Overall, the risks for companies appeared to be manageable, the profits of the corporations could be affected in the low to medium single -digit percentage range. Novo Nordisk would be the least affected and the most strongest.
Analysis and stock assessment: An investigation of the Merck share at the time of the analysis
The Merck share noted in green in Xetra trading at 1:34 p.m. and won 1.4 percent to EUR 114.20. With this, the share participation still has room for improvement of 28.72 percent compared to the price target. So far, 89,883 Merck shares have been traded today. The paper dropped by 16.9 percent since the beginning of 2025.
New York (dpa-AfX analyzer) / Redaktion finanzen.net
Publication of the original study: 28.07.2025 / 06:49 / UTC
First passing on of the original study: 28.07.2025 / 06:49 / UTC
Note: Information on the obligation to disclose the disclosure for conflicts of interest within the meaning of Section 85 (1) WPHG, Art. 20 VO (EU) 596/2014 For the Analysten House mentioned can be found at http://web.dpa-afx.de/offengegungs-
Selected leverage products on Merck
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired lever and we will show you suitable open-end products on Merck
The lever must be between 2 and 20
Advertising